Who are Oxybuprocaine/fluorescein SDU's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cordarone, MEXILETINE HYDROCHLORIDE, Norpace Cr, Bupivacaine Hydrochloride And Epinephrine, Bupivacaine Hydrochloride And Epinephrine, Bupivacaine Hydrochloride And Epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxybuprocaine-fluorescein-sdu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oxybuprocaine/fluorescein SDU — Competitive Intelligence Brief

Oxybuprocaine/fluorescein SDU (Oxybuprocaine/fluorescein SDU) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Ophthalmology.

phase 3 Local anesthetic Sodium channels Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Oxybuprocaine/fluorescein SDU (Oxybuprocaine/fluorescein SDU) — Medical University of Vienna. Oxybuprocaine/fluorescein SDU is a local anesthetic and a fluorescent dye used to visualize the corneal endothelium.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxybuprocaine/fluorescein SDU TARGET	Oxybuprocaine/fluorescein SDU	Medical University of Vienna	phase 3	Local anesthetic	Sodium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
MEXILETINE HYDROCHLORIDE	MEXILETINE HYDROCHLORIDE		marketed		sodium channels	1985-01-01
Norpace Cr	Disopyramide Phosphate	Pfizer	marketed	Type 1 antiarrhythmic	Cardiac sodium channels; cardiac cells with augmented automaticity	1977-01-01
Bupivacaine Hydrochloride And Epinephrine	Bupivacaine Hydrochloride	Pfizer	marketed	Amide local anesthetic	Nerve sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	Bupivacaine Hydrochloride	Pfizer	marketed	Local anesthetic	Sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	Bupivacaine Hydrochloride	Pfizer	marketed	Amide local anesthetic	Nerve sodium channels	1972-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

University of California, San Diego · 3 drugs in this class
Durect · 3 drugs in this class
Pacira Pharmaceuticals, Inc · 3 drugs in this class
Wake Forest University Health Sciences · 3 drugs in this class
Medical University of Vienna · 3 drugs in this class
Imperial College London · 2 drugs in this class
Hvidovre University Hospital · 2 drugs in this class
Innocoll · 2 drugs in this class
George Washington University · 2 drugs in this class
Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxybuprocaine/fluorescein SDU — Competitive Intelligence Brief. https://druglandscape.com/ci/oxybuprocaine-fluorescein-sdu. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab